MedPath

Efficacy of Topical Cyclosporine 0.05% in the Prevention of Ocular Surface Inflammation Secondary to Pterygia

Phase 4
Completed
Conditions
Pterygia
Registration Number
NCT00383396
Lead Sponsor
Innovative Medical
Brief Summary

To Determine if topical cyclosporine 0.05% BID prevents recurrent inflammation and improves comfort in eyes with pterygia.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
Not specified
Inclusion Criteria
  • pts with symptomatic pterygia unresponsive to palliative treatment.
Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Dr. Schechter

🇺🇸

Boynton Beach, Florida, United States

© Copyright 2025. All Rights Reserved by MedPath